Key result
A high VTE Clinical Risk Score predicted higher 120-day mortality (12.7% vs 1.4%; aHR 3.00, 95% CI 1.4-6.3) and cancer progression compared to a low score in adults initiating chemotherapy.
Why the study?
Does a validated VTE Clinical Risk Score predict early mortality and cancer progression in adults with solid tumors or lymphoma initiating chemotherapy?
Population
4,405 adults with solid tumors or lymphoma initiating chemotherapy at 115 U.S. practice sites
Comparison
High or intermediate risk classification by a… vs Low risk classification by the VTE Clinical Risk…
Design
Cohort
Follow-up
median 75 days
Authors
Loading...
May aid VTE risk stratification at chemotherapy start; hypothesis-generating for prospective validation before practice change.
Cohort (n=4,405)
Yes
Does a validated VTE Clinical Risk Score predict early mortality and cancer progression in adults with solid tumors or lymphoma initiating chemotherapy?
Hazard Ratio: 3 (95% CI 1.4–6.3)
Absolute Event Rate: 12.7% vs 1.4%
A validated VTE Clinical Risk Score independently predicts early mortality and cancer progression in patients receiving outpatient chemotherapy.
Kuderer et al. (2016) conducted a cohort in Solid tumors or lymphoma (n=4,405). High VTE Clinical Risk Score vs. Low VTE Clinical Risk Score was evaluated on 120-day mortality (aHR 3.00, 95% CI 1.4-6.3). A high VTE Clinical Risk Score predicted higher 120-day mortality (12.7% vs 1.4%; aHR 3.00, 95% CI 1.4-6.3) and cancer progression compared to a low score in adults initiating chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: